|
Video: What is a Stock Split?
|
|
BeiGene is a commercial-stage biotechnology company focused on developing and commercializing molecularly-targeted and immuno-oncology cancer therapeutics. Co.'s clinical-stage drug candidates include: Zanubrutinib, which is a small molecule inhibitor of Bruton's tyrosine kinase for the treatment of mantle cell lymphoma in adult patients; Tislelizumab, which is a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1; Pamiparib (BGB-290), which is for the treatment of various solid tumors; and Lifirafenib, which is an investigational small molecule inhibitor with RAF monomer and dimer inhibition activities. According to our BeiGene stock split history records, BeiGene has had 0 splits. | |
|
BeiGene (BGNE) has 0 splits in our BeiGene stock split history database.
Looking at the BeiGene stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into BeiGene shares, starting with a $10,000 purchase of BGNE, presented on a split-history-adjusted basis factoring in the complete BeiGene stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
02/05/2016 |
|
End date: |
04/23/2024 |
|
Start price/share: |
$33.91 |
|
End price/share: |
$138.99 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
309.88% |
|
Average Annual Total Return: |
18.73% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$40,984.67 |
|
Years: |
8.22 |
|
|
|
|
|